Department of Medical Oncology, Cancer Center and Laboratory of Molecular, Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China.
J Exp Clin Cancer Res. 2021 May 18;40(1):173. doi: 10.1186/s13046-021-01971-1.
Serotonin signaling has been associated with tumorigenesis and tumor progression. Targeting the serotonin transporter to block serotonin cellular uptake confers antineoplastic effects in various tumors, including colon cancer. However, the antineoplastic mechanism of serotonin transporter inhibition and serotonin metabolism alterations in the absence of serotonin transporter have not been elucidated, especially in colon cancer, which might limit anti-tumor effects associating with targeting serotonin transporter.
The promotion in the uptake and catabolism of extracellular tryptophan and targeting serotonin transporter was detected by using quantitative reverse-transcription polymerase chain reaction, western blotting and liquid chromatography tandem mass spectrometry. Western blotting Immunoprecipitation and immunofluorescence was utilized to research the serotonylation of mTOR by serotonin and serotonin transporter inhibition. The primary mouse model, homograft model and tissue microarry was used to explore the tryptophan pathway in colon cancer. The cell viability assay, western blotting, xenograft and primary colon cancer mouse model were used to identify whether the combination of sertraline and tryptophan restriction had a synergistic effect.
Targeting serotonin transporter through genetic ablation or pharmacological inhibition in vitro and in vivo induced a compensatory effect by promoting the uptake and catabolism of extracellular tryptophan in colon cancer. Mechanistically, targeting serotonin transporter suppressed mTOR serotonylation, leading to mTOR inactivation and increased tryptophan uptake. In turn, this process promoted serotonin biosynthesis and oncogenic metabolite kynurenine production through enhanced tryptophan catabolism. Tryptophan deprivation, or blocking its uptake by using trametinib, a MEK inhibitor, can sensitize colon cancer to selective serotonin reuptake inhibitors.
The present study elucidated a novel feedback mechanism involved in the regulation of serotonin homeostasis and suggested innovative strategies for selective serotonin reuptake inhibitors-based treatment of colon cancer.
血清素信号与肿瘤发生和肿瘤进展有关。靶向血清素转运体以阻止血清素细胞摄取在各种肿瘤中赋予抗肿瘤作用,包括结肠癌。然而,在没有血清素转运体的情况下,血清素转运体抑制和血清素代谢改变的抗肿瘤机制尚未阐明,特别是在结肠癌中,这可能限制了与靶向血清素转运体相关的抗肿瘤作用。
通过定量逆转录聚合酶链反应、蛋白质印迹和液相色谱串联质谱检测细胞外色氨酸摄取和分解代谢的促进作用。Western blotting 免疫沉淀和免疫荧光用于研究血清素和血清素转运体抑制对 mTOR 的血清素化作用。利用原发性小鼠模型、同种移植模型和组织微阵列来研究结肠癌中的色氨酸途径。细胞活力测定、蛋白质印迹、异种移植和原发性结肠癌小鼠模型用于鉴定舍曲林和色氨酸限制的联合使用是否具有协同作用。
体外和体内通过基因消融或药理学抑制靶向血清素转运体诱导了一种代偿效应,通过促进结肠癌中外源色氨酸的摄取和分解代谢。从机制上讲,靶向血清素转运体抑制 mTOR 的血清素化,导致 mTOR 失活和色氨酸摄取增加。反过来,这一过程通过增强色氨酸分解代谢促进了血清素生物合成和致癌代谢物犬尿氨酸的产生。色氨酸剥夺,或使用 MEK 抑制剂 trametinib 阻断其摄取,可以使结肠癌对选择性血清素再摄取抑制剂敏感。
本研究阐明了涉及血清素动态平衡调节的新反馈机制,并提出了基于选择性血清素再摄取抑制剂治疗结肠癌的创新策略。